Full Year 2018 Oxford BioMedica PLC Earnings Call Transcript
Good day, ladies and gentlemen, and welcome to the Oxford Biomedica Preliminary Results 2018 Webcast and Conference Call. Your speakers for today are John Dawson, CEO; Stuart Paynter, CFO; and Catherine Isted, Head of Corporate Development and IR. (Operator Instructions) As a reminder, today's conference call is being recorded. (Operator Instructions)
Good afternoon, and welcome to Oxford Biomedica's preliminary results for 2018. I'd like to thank you all of you in the room and those online and on the webcast for joining us today.
The word transformational is a word I believe is often overused. However, I do think it's correct to say that 2018 has truly been a transformational year for Oxford Biomedica. Not only have we seen our revenue grow by 70%, we have also become EBITDA and cash flow positive. Importantly this year, we have proved to the markets that our dual strategy is working with both large platform and pipeline deals signed. We're now building for the future in
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |